The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume - PubMed (original) (raw)
The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume
J A Whitworth et al. J Hypertens. 1989 Jul.
Abstract
In previous studies, administration of adrenocorticotrophin (ACTH; 0.5 mg i.m. b.d. for 5 days) to normal subjects produced an adrenally dependent rise in blood pressure (BP) of some 20 mmHg, accompanied by an increase in cardiac output and an increase in plasma volume. The BP and metabolic effects of ACTH (increase in plasma glucose, fall in eosinophils, increase in body weight and urine sodium retention) were reproduced by infusion of the glucocorticoid (GC) cortisol at rates (6-8 mg/h) which reproduced the blood concentrations of the steroid achieved with ACTH administration. Oral administration (hydrocortisone 200 mg daily) produced similar changes qualitatively, although the cortisol concentrations and increase in pressure (12 mmHg) were less. Plasma volume was increased. To determine the role of urine sodium retention and plasma volume expansion in the hypertension, we gave synthetic steroids to six normal subjects for 5 days, at doses which were calculated to be similar for GC activity, but which had little or no mineralocorticoid (MC) activity. Prednisolone (40 mg/day), methylprednisolone (32 mg/day), triamcinolone (40 mg/day) and dexamethasone (8 mg/day) all produced equivalent GC effects (increase in plasma glucose, increase in total white cell count, fall in direct eosinophil count). There were no MC effects with any of the steroids. Body weight did not increase and urinary sodium excretion increased rather than decreased. Plasma volume (125I human serum albumin) and haematocrit were unchanged. BP rose with all four steroids: systolic BP rose by 13 mmHg with prednisolone, by 9 mmHg with methylprednisolone, by 10 mmHg with triamcinolone, and by 6 mmHg with dexamethasone. Diastolic BP increases were 8, 11, 8 and 7 mmHg, respectively. Thus, neither MC activity nor an increase in plasma volume is essential for steroids to induce an increase in blood pressure. Therefore, screening of synthetic GCs to minimize MC activity will not prevent hypertensive complications.
Similar articles
- Blood pressure and metabolic effects of cortisol and deoxycorticosterone in man.
Whitworth JA, Saines D, Scoggins BA. Whitworth JA, et al. Clin Exp Hypertens A. 1984;6(4):795-809. doi: 10.3109/10641968409044039. Clin Exp Hypertens A. 1984. PMID: 6723088 - Adrenocorticotrophin and steroid-induced hypertension in humans.
Whitworth JA. Whitworth JA. Kidney Int Suppl. 1992 Jun;37:S34-7. Kidney Int Suppl. 1992. PMID: 1321309 Review. - A 'hypertensinogenic' class of steroid hormone activity in man?
Whitworth JA, Scoggins BA. Whitworth JA, et al. Clin Exp Pharmacol Physiol. 1990 Mar;17(3):163-6. doi: 10.1111/j.1440-1681.1990.tb01299.x. Clin Exp Pharmacol Physiol. 1990. PMID: 2160339 - Steroid antagonism of the hypertensinogenic activity of adrenocortical steroids.
Reid AF, Spence CD, Coghlan JP, Denton DA, Whitworth JA, Scoggins BA. Reid AF, et al. J Steroid Biochem. 1987;27(4-6):977-83. doi: 10.1016/0022-4731(87)90177-4. J Steroid Biochem. 1987. PMID: 2826916 - Cortisol and hypertension.
Kelly JJ, Mangos G, Williamson PM, Whitworth JA. Kelly JJ, et al. Clin Exp Pharmacol Physiol Suppl. 1998 Nov;25:S51-6. doi: 10.1111/j.1440-1681.1998.tb02301.x. Clin Exp Pharmacol Physiol Suppl. 1998. PMID: 9809193 Review.
Cited by
- New-onset acute heart failure after intravenous glucocorticoid pulse therapy in a patient with Graves' ophthalmopathy.
Gursoy A, Cesur M, Erdogan MF, Corapcioglu D, Kamel N. Gursoy A, et al. Endocrine. 2006 Jun;29(3):513-6. doi: 10.1385/ENDO:29:3:513. Endocrine. 2006. PMID: 16943591 - Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor.
Whitworth JA, Kelly JJ. Whitworth JA, et al. J Endocrinol Invest. 1995 Jul-Aug;18(7):586-91. doi: 10.1007/BF03349774. J Endocrinol Invest. 1995. PMID: 9221279 No abstract available. - Cushing's syndrome: all variants, detection, and treatment.
Sharma ST, Nieman LK. Sharma ST, et al. Endocrinol Metab Clin North Am. 2011 Jun;40(2):379-91, viii-ix. doi: 10.1016/j.ecl.2011.01.006. Endocrinol Metab Clin North Am. 2011. PMID: 21565673 Free PMC article. - Impact of renal dysfunction on in-hospital mortality of patients with severe chronic obstructive pulmonary disease: a single-center Italian study.
Fabbian F, De Giorgi A, Manfredini F, Lamberti N, Forcellini S, Storari A, Gallerani M, Caramori G, Manfredini R. Fabbian F, et al. Int Urol Nephrol. 2016 Jul;48(7):1121-7. doi: 10.1007/s11255-016-1272-5. Epub 2016 Mar 28. Int Urol Nephrol. 2016. PMID: 27020445 - Effects of mineralocorticoid receptor blockade on glucocorticoid-induced renal injury in adrenalectomized rats.
Rafiq K, Nakano D, Ihara G, Hitomi H, Fujisawa Y, Ohashi N, Kobori H, Nagai Y, Kiyomoto H, Kohno M, Nishiyama A. Rafiq K, et al. J Hypertens. 2011 Feb;29(2):290-8. doi: 10.1097/hjh.0b013e32834103a9. J Hypertens. 2011. PMID: 21243738 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous